Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.76 | ||
| Price to Tang. Book | 5.76 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -25.33% | ||
| Return on Equity | -19.67% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- March 29th, 2021
- Public Since
- June 25th, 2021
- No. of Shareholders
- 4
- No. of Employees
- 73
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 68,557,174
- Address
- Joshua Dawson House Dawson Street, Dublin, D02RY95
- Web
- https://www.ghres.com
- Phone
- +353 14378334
- Auditors
- PricewaterhouseCoopers SA
Upcoming Events for GHRS
Similar to GHRS
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
What is the GH Research share price?
As of Today at 11:51 UTC, shares in GH Research are trading at $22.12. This share price information is delayed by 15 minutes.
How has the GH Research share price performed this year?
Shares in GH Research last closed at $22.12 and the price had moved by +96.27% over the past 365 days. In terms of relative price strength the GH Research share price has outperformed the S&P500 Index by +52.4% over the past year.
What are the analyst and broker recommendations for GH Research?
The overall consensus recommendation for GH Research is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the GH Research dividend yield?
GH Research does not currently pay a dividend.
Does GH Research pay a dividend?
GH Research does not currently pay a dividend.
When does GH Research next pay dividends?
GH Research does not currently pay a dividend.
How do I buy GH Research shares?
To buy shares in GH Research you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of GH Research?
As of the previous close price of $22.12, shares in GH Research had a market capitalisation of $1.52bn.
Where are GH Research shares listed?
Here are the trading details for GH Research:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: GHRS
What kind of share is GH Research?
Based on an overall assessment of its quality, value and momentum GH Research is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a GH Research share price forecast for 2026?
The analyst consensus target price for shares in GH Research is $39.50. That is 78.57% above the last closing price of $22.12.
Analysts covering GH Research currently have a consensus Earnings Per Share (EPS) forecast of -$1.39 for the next financial year.
Find out moreWhat is the trend in the GH Research share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GH Research. Over the past six months, its share price has outperformed the S&P500 Index by +41.6%.
As of the last closing price of $22.12, shares in GH Research were trading +46.17% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the GH Research PE Ratio?
The GH Research PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $22.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of GH Research?
We do not have data on GH Research's directors